Attached files

file filename
8-K - 8-K - Ventas, Inc.june2014form8-kbodyproform.htm
EX-99.2 - EXHIBIT 99.2 - Ventas, Inc.exhibit992hct123113.htm
EX-99.1 - EXHIBIT 99.1 - Ventas, Inc.exhibit991hct063014.htm
EX-23.1 - EXHIBIT 23.1 - Ventas, Inc.exhibit231grantthorntoncon.htm
Exhibit 99.3

VENTAS, INC.
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
As of and For the Six Months Ended June 30, 2014 and For the Year Ended December 31, 2013
 
On June 2, 2014, Ventas, Inc. (“Ventas” or the “Company”) announced that it had entered into a definitive agreement to acquire all of the outstanding shares of American Realty Capital Healthcare Trust, Inc. (“HCT”) in a stock and cash transaction valued at $2.9 billion, or $11.33 per HCT share, including investments expected to be made by HCT prior to completion of the acquisition, the majority of which have now been completed.
 
The following unaudited pro forma condensed consolidated financial information sets forth:
 
The historical consolidated financial information of Ventas as of and for the six months ended June 30, 2014, derived from Ventas’s unaudited consolidated financial statements, and the historical consolidated statement of income information of Ventas for the year ended December 31, 2013, derived from Ventas’s audited consolidated financial statements;

Pro forma adjustments to give effect to Ventas’s August 2014 acquisition of 29 independent living seniors housing communities located in Canada on Ventas’s consolidated balance sheet as of June 30, 2014, as if the acquisition closed on June 30, 2014;

Pro forma adjustments to give effect to Ventas’s 2014 and 2013 acquisitions and other investments, dispositions and significant debt activity (including the August 2014 acquisition of 29 independent living seniors housing communities located in Canada and the April 2014 issuance and sale of $700 million aggregate principal amount of senior notes) on Ventas’s consolidated statements of income for the six months ended June 30, 2014 and for the year ended December 31, 2013, as if these transactions occurred on January 1, 2013;

The historical consolidated financial information of HCT as of and for the six months ended June 30, 2014, derived from HCT’s unaudited consolidated financial statements, and the historical consolidated statement of income information of HCT for the year ended December 31, 2013, derived from HCT’s audited consolidated financial statements;

Pro forma adjustments to give effect to HCT’s 2014 and 2013 acquisitions and other investments, dispositions and significant debt activity on HCT’s consolidated statements of income for the six months ended June 30, 2014 and for the year ended December 31, 2013, as if these transactions occurred on January 1, 2013;

Pro forma adjustments to give effect to Ventas’s acquisition of HCT on Ventas’s consolidated balance sheet as of June 30, 2014, as if the acquisition closed on June 30, 2014; and

Pro forma adjustments to give effect to Ventas’s acquisition of HCT on Ventas’s consolidated statements of income for the six months ended June 30, 2014 and for the year ended December 31, 2013, as if the acquisition closed on January 1, 2013.
 
These unaudited pro forma condensed consolidated financial statements have been prepared for informational purposes only and are based on assumptions and estimates considered appropriate by Ventas’s management; however, they are not necessarily indicative of what Ventas’s consolidated financial condition or results of operations actually would have been assuming the transactions had been consummated as of the dates indicated, nor do they purport to represent Ventas’s consolidated financial position or results of operations for future periods. These unaudited pro forma condensed consolidated financial statements do not include the impact of any synergies that may be achieved in the transactions or any strategies that management may consider in order to continue to efficiently manage Ventas’s operations.  This pro forma condensed consolidated financial information should be read in conjunction with:
 
Ventas’s unaudited consolidated financial statements and the related notes thereto as of and for the six months ended June 30, 2014 included in the Company’s Quarterly Report on Form 10-Q for the quarter then ended, filed with the Securities and Exchange Commission (“SEC”) on August 11, 2014;

Ventas’s audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2013 included in the Company’s Annual Report on Form 10-K for the year then ended, filed with the SEC on February 18, 2014, as amended by Amendment No. 1 to the Company’s Annual Report on Form 10-K/A, filed with the SEC on September 4, 2014;



HCT’s unaudited consolidated financial statements and the related notes thereto as of and for the six months ended June 30, 2014 included in HCT’s Quarterly Report on Form 10-Q for the quarter then ended, filed with the SEC on August 12, 2014; and

HCT’s audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2013 included in HCT’s Annual Report on Form 10-K for the year then ended, filed with the SEC on February 26, 2014.
 
The acquisition of HCT will be accounted for using the acquisition method of accounting in accordance with Accounting Standards Codification Topic 805, Business Combinations.  The total purchase price of approximately $2.9 billion will be allocated to the assets ultimately acquired and liabilities ultimately assumed based upon their respective fair values.  The allocations of the purchase price reflected in these unaudited pro forma condensed consolidated financial statements have not been finalized and are based upon preliminary estimates of these fair values, which is the best available information at the current time. A final determination of the fair values of the assets acquired and liabilities assumed, which cannot be made prior to the completion of the acquisition, will be based on the actual valuations of the tangible and intangible assets and liabilities that exist as of the date of completion of the acquisition. Consequently, amounts preliminarily allocated to identifiable tangible and intangible assets and liabilities could change significantly from those used in the unaudited pro forma condensed consolidated financial statements and could result in a material change in depreciation and amortization of tangible and intangible assets and liabilities.
 
The completion of the valuation, the allocation of purchase price, the impact of ongoing integration activities, the timing of completion of the acquisition and other changes in tangible and intangible assets and liabilities that occur prior to completion of the acquisition could cause material differences in the information presented herein.




VENTAS, INC.
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET
As of June 30, 2014
(In thousands)

 
Ventas Historical
 
Ventas 2014 Transactions Adjustments (A)
 
Pro Forma for Ventas 2014 Transactions
 
HCT Historical (B)
 
HCT Acquisition Adjustments (C)
 
 
 
Total Pro Forma
Assets
 
 
 
 
 
 
 
 
 
 
 
 
 
Net real estate investments
$
18,389,744

 
$
1,004,635

 
$
19,394,379

 
$
1,972,317

 
$
738,501

 
(D)
 
$
22,105,197

Cash and cash equivalents
86,635

 
43,669

 
130,304

 
28,695

 

 
 
 
158,999

Escrow deposits and restricted cash
75,514

 

 
75,514

 
2,135

 

 
 
 
77,649

Deferred financing costs, net
63,399

 
4,701

 
68,100

 
19,287

 
(19,287
)
 
(E)
 
68,100

Other assets
1,175,494

 
(36,287
)
 
1,139,207

 
55,091

 
82,300

 
(F)
 
1,276,598

Total assets
$
19,790,786

 
$
1,016,718

 
$
20,807,504

 
$
2,077,525

 
$
801,514

 
 
 
$
23,686,543

Liabilities and equity
 
 
 
 
 
 
 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
Senior notes payable and other debt
$
9,602,439

 
$
923,641

 
$
10,526,080

 
$
815,707

 
$
198,783

 
(G)
 
$
11,540,570

Accrued interest
56,722

 

 
56,722

 
1,540

 

 
 
 
58,262

Accounts payable and other liabilities
975,282

 
11,644

 
986,926

 
95,634

 
(37,676
)
 
(H)
 
1,044,884

Deferred income taxes
256,392

 
107,026

 
363,418

 

 

 
 
 
363,418

Total liabilities
10,890,835

 
1,042,311

 
11,933,146

 
912,881

 
161,107

 
 
 
13,007,134

Redeemable OP unitholder and noncontrolling interests
169,292

 

 
169,292

 

 
79,959

 
(I)
 
249,251

Commitments and contingencies
 
 
 
 
 
 
 
 
 
 
 
 
 
Equity:
 
 
 
 
 
 
 
 
 
 
 
 
 
Total Ventas stockholders' equity
8,655,110

 
(25,593
)
 
8,629,517

 
1,150,157

 
574,935

 
(J)
 
10,354,609

Noncontrolling interest
75,549

 

 
75,549

 
14,487

 
(14,487
)
 
(K)
 
75,549

Total equity
8,730,659

 
(25,593
)
 
8,705,066

 
1,164,644

 
560,448

 
 
 
10,430,158

Total liabilities and equity
$
19,790,786

 
$
1,016,718

 
$
20,807,504

 
$
2,077,525

 
$
801,514

 
 
 
$
23,686,543

See accompanying notes to unaudited pro forma condensed consolidated financial statements.




VENTAS, INC.
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF INCOME
For the six months ended June 30, 2014
(In thousands, except per share amounts)
 
Ventas Historical
 
Ventas 2014 Transactions Adjustments (L)
 
Pro Forma for Ventas 2014 Transactions
 
HCT Historical (B)
 
HCT 2014 Transactions Adjustments (L)
 
Pro Forma for HCT 2014 Transactions
 
HCT Acquisition Adjustments (C)
 
 
 
Total Pro Forma
Revenues:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rental income:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Triple-net leased
$
480,572

 
$
4,136

 
$
484,708

 
$
13,218

 
$
4,823

 
$
18,041

 
$
131

 
(M)
 
$
502,880

Medical office buildings
230,113

 
(209
)
 
229,904

 
48,939

 
964

 
49,903

 
(162
)
 
(M)
 
279,645

 
710,685

 
3,927

 
714,612

 
62,157

 
5,787

 
67,944

 
(31
)
 
 
 
782,525

Resident fees and services
745,534

 
58,218

 
803,752

 
58,214

 
11,321

 
69,535

 

 
 
 
873,287

Medical office building and other services revenue
10,667

 

 
10,667

 

 

 

 

 
 
 
10,667

Income from loans and investments
25,392

 
2,059

 
27,451

 
1,130

 

 
1,130

 
(12
)
 
(N)
 
28,569

Interest and other income
446

 

 
446

 

 

 

 

 
 
 
446

Total revenues
1,492,724

 
64,204

 
1,556,928

 
121,501

 
17,108

 
138,609

 
(43
)
 
 
 
1,695,494

Expenses:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interest
179,342

 
13,760

 
193,102

 
12,651

 
359

 
13,010

 
(1,788
)
 
(O)
 
204,324

Depreciation and amortization
384,412

 
29,424

 
413,836

 
60,656

 
7,303

 
67,959

 
(18,520
)
 
(P)
 
463,275

Property-level operating expenses:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Senior living
497,719

 
28,628

 
526,347

 
41,532

 
7,650

 
49,182

 

 
 
 
575,529

Medical office buildings
78,680

 
(39
)
 
78,641

 
10,150

 
290

 
10,440

 

 
 
 
89,081

 
576,399

 
28,589

 
604,988

 
51,682

 
7,940

 
59,622

 

 
 
 
664,610

Medical office building services costs
4,997

 

 
4,997

 

 

 

 

 
 
 
4,997

General, administrative and professional fees
64,172

 

 
64,172

 
4,057

 

 
4,057

 

 
 
 
68,229

Loss (gain) on extinguishment of debt, net
2,665

 
(243
)
 
2,422

 

 

 

 

 
 
 
2,422

Merger-related expenses and deal costs
20,359

 
(8,398
)
 
11,961

 
25,878

 
(6,428
)
 
19,450

 

 
 
 
31,411

Other
10,092

 

 
10,092

 
71,067

 

 
71,067

 
(71,067
)
 
(Q)
 
10,092

Total expenses
1,242,438

 
63,132

 
1,305,570

 
225,991

 
9,174

 
235,165

 
(91,375
)
 
 
 
1,449,360

Income (loss) before income from unconsolidated entities, income taxes, discontinued operations, real estate dispositions and noncontrolling interest
250,286

 
1,072

 
251,358

 
(104,490
)
 
7,934

 
(96,556
)
 
91,332

 
 
 
246,134

Income from unconsolidated entities
596

 
36

 
632

 

 

 

 

 
 
 
632

Income tax expense
(6,707
)
 

 
(6,707
)
 
(642
)
 

 
(642
)
 

 
 
 
(7,349
)
Income from continuing operations
244,175

 
1,108

 
245,283

 
(105,132
)
 
7,934

 
(97,198
)
 
91,332

 
 
 
239,417

Gain (loss) on real estate dispositions, net
12,889

 
(14,771
)
 
(1,882
)
 

 

 

 

 
 
 
(1,882
)
Income (loss) from continuing operations, including real estate dispositions
257,064

 
(13,663
)
 
243,401

 
(105,132
)
 
7,934

 
(97,198
)
 
91,332

 
 
 
237,535

Net income (loss) attributable to noncontrolling interest
395

 

 
395

 
(808
)
 

 
(808
)
 
808

 
(R)
 
395

Income (loss) from continuing operations attributable to common stockholders, including real estate dispositions
$
256,669

 
$
(13,663
)
 
$
243,006

 
$
(104,324
)
 
$
7,934

 
$
(96,390
)
 
$
90,524

 
 
 
$
237,140

Income (loss) from continuing operations attributable to common stockholders per common share:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic
$
0.87

 
$

 
$
0.83

 
$
(0.58
)
 
$

 
$
(0.54
)
 
N/A
 
 
 
$
0.74

Diluted
$
0.87

 
$

 
$
0.82

 
$
(0.58
)
 
$

 
$
(0.54
)
 
N/A
 
 
 
$
0.73

Weighted average shares used in computing earnings per common share:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic
293,932

 

 
293,932

 
178,357

 

 
178,357

 
25,723

 
(S)
 
319,655

Diluted
296,369

 

 
296,369

 
178,357

 

 
178,357

 
26,914

 
(S)
 
323,283

See accompanying notes to unaudited pro forma condensed consolidated financial statements.



VENTAS, INC.
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF INCOME
For the year ended December 31, 2013
(In thousands, except per share amounts)
 
Ventas Historical
 
Ventas 2014 and 2013 Transactions Adjustments (L)
 
Pro Forma for Ventas 2014 and 2013 Transactions
 
HCT Historical (B)
 
HCT 2014 and 2013 Transactions Adjustments (L)
 
Pro Forma for HCT 2014 and 2013 Transactions
 
HCT Acquisition Adjustments (C)
 
 
 
Total Pro Forma
Revenues:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rental income:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Triple-net leased
$
875,877

 
$
63,404

 
$
939,281

 
$
12,880

 
$
15,600

 
$
28,480

 
$
261

 
(M)
 
$
968,022

Medical office buildings
450,107

 
5,208

 
455,315

 
64,075

 
31,314

 
95,389

 
(258
)
 
(M)
 
550,446

 
1,325,984

 
68,612

 
1,394,596

 
76,955

 
46,914

 
123,869

 
3

 
 
 
1,518,468

Resident fees and services
1,406,005

 
180,806

 
1,586,811

 
47,698

 
67,768

 
115,466

 

 
 
 
1,702,277

Medical office building and other services revenue
17,809

 
596

 
18,405

 

 

 

 

 
 
 
18,405

Income from loans and investments
58,208

 
(2,573
)
 
55,635

 
569

 

 
569

 
(13
)
 
(N)
 
56,191

Interest and other income
2,047

 
1

 
2,048

 
89

 

 
89

 

 
 
 
2,137

Total revenues
2,810,053

 
247,442

 
3,057,495

 
125,311

 
114,682

 
239,993

 
(10
)
 
 
 
3,297,478

Expenses:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interest
334,484

 
65,650

 
400,134

 
15,843

 
2,884

 
18,727

 
1,459

 
(O)
 
420,320

Depreciation and amortization
721,959

 
108,216

 
830,175

 
67,456

 
60,583

 
128,039

 
4,960

 
(P)
 
963,174

Property-level operating expenses:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Senior living
956,684

 
94,666

 
1,051,350

 
33,151

 
42,137

 
75,288

 

 
 
 
1,126,638

Medical office buildings
152,948

 
3,069

 
156,017

 
12,814

 
5,013

 
17,827

 

 
 
 
173,844

 
1,109,632

 
97,735

 
1,207,367

 
45,965

 
47,150

 
93,115

 

 
 
 
1,300,482

Medical office building services costs
8,315

 

 
8,315

 

 

 

 

 
 
 
8,315

General, administrative and professional fees
115,106

 
(5
)
 
115,101

 
4,089

 

 
4,089

 

 
 
 
119,190

Loss on extinguishment of debt, net
1,201

 
243

 
1,444

 

 

 

 

 
 
 
1,444

Merger-related expenses and deal costs
21,634

 
(7,276
)
 
14,358

 
13,606

 
(15,239
)
 
(1,633
)
 

 
 
 
12,725

Other
18,732

 

 
18,732

 

 

 

 

 
 
 
18,732

Total expenses
2,331,063

 
264,563

 
2,595,626

 
146,959

 
95,378

 
242,337

 
6,419

 
 
 
2,844,382

Income (loss) before (loss) income from unconsolidated entities, income taxes, discontinued operations, real estate dispositions and noncontrolling interest
478,990

 
(17,121
)
 
461,869

 
(21,648
)
 
19,304

 
(2,344
)
 
(6,429
)
 
 
 
453,096

(Loss) income from unconsolidated entities
(508
)
 
493

 
(15
)
 

 

 

 

 
 
 
(15
)
Income tax benefit (expense)
11,828

 

 
11,828

 
(524
)
 

 
(524
)
 

 
 
 
11,304

Income (loss) from continuing operations
490,310

 
(16,628
)
 
473,682

 
(22,172
)
 
19,304

 
(2,868
)
 
(6,429
)
 
 
 
464,385

Gain on real estate dispositions, net

 
14,771

 
14,771

 

 

 

 
 
 
 
 
14,771

Income (loss) from continuing operations, including real estate dispositions
490,310

 
(1,857
)
 
488,453

 
(22,172
)
 
19,304

 
(2,868
)
 
(6,429
)
 
 
 
479,156

Net income attributable to noncontrolling interest
1,380

 
143

 
1,523

 
58

 

 
58

 
(58
)
 
(R)
 
1,523

Income (loss) from continuing operations attributable to common stockholders
$
488,930

 
$
(2,000
)
 
$
486,930

 
$
(22,230
)
 
$
19,304

 
$
(2,926
)
 
$
(6,371
)
 
 
 
$
477,633

Income (loss) from continuing operations attributable to common stockholders per common share:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic
$
1.67

 
$

 
$
1.66

 
$
(0.15
)
 
$

 
$
(0.02
)
 
N/A
 
 
 
$
1.50

Diluted
$
1.66

 
$

 
$
1.65

 
$
(0.15
)
 
$

 
$
(0.02
)
 
N/A
 
 
 
$
1.48

Weighted average shares used in computing earnings per common share:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic
292,654

 

 
292,654

 
151,684

 

 
151,684

 
25,723

 
(S)
 
318,377

Diluted
295,110

 

 
295,110

 
151,684

 

 
151,684

 
26,914

 
(S)
 
322,024

See accompanying notes to unaudited pro forma condensed consolidated financial statements.



VENTAS, INC.
 NOTES AND MANAGEMENT’S ASSUMPTIONS TO UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
 
NOTE 1 - BASIS OF PRO FORMA PRESENTATION
 
Ventas, Inc. (“Ventas” or the “Company”) is a real estate investment trust (“REIT”) with a geographically diverse portfolio of seniors housing and healthcare properties in the United States, Canada and the United Kingdom.  The historical consolidated financial statements of Ventas include the accounts of the Company and its wholly owned subsidiaries and joint venture entities over which it exercises control.
 
On June 2, 2014, Ventas announced that it had entered into a definitive agreement to acquire all of the outstanding shares of American Realty Capital Healthcare Trust, Inc. (“HCT”) in a stock and cash transaction valued at $2.9 billion, or $11.33 per HCT share, including investments expected to be made by HCT prior to the acquisition, the majority of which have now been completed.

NOTE 2 - ADJUSTMENTS TO UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET

(A) Adjustments reflect the effect on Ventas’s historical consolidated balance sheet of its August 2014 acquisition of 29 independent living seniors housing communities located in Canada, a portion of which was funded through borrowings under a new CAD 791 million unsecured term loan, as if this transaction closed on June 30, 2014.

(B) Reflects historical consolidated financial condition or results of operations of HCT as of or for the six months ended June 30, 2014 or for the year ended December 31, 2013.  Certain amounts have been reclassified to conform to Ventas’s presentation.

(C) Reflects adjustments to record the acquisition of HCT by Ventas based upon the estimated purchase price of approximately $2.9 billion.  The calculation of the estimated purchase price to be allocated is as follows (in millions, except per share amounts):

Equity to be issued (26.9 million shares at $67.13 per share)
$
1,806

Cash to be paid (assumed to be funded with borrowings under Ventas’s unsecured revolving credit facility)
192

Assumption or repayment of net debt
930

Estimated purchase price
$
2,928

 
 

(D) Reflects adjustment to record the estimated increase over HCT’s historical investment in real estate based upon the preliminary estimated fair value for the tangible and intangible real estate assets to be acquired.  These estimated values are as follows (in millions):

Land and improvements
 
$
266

Buildings and improvements
 
2,219

Acquired lease intangibles
 
225

Estimated fair value of net real estate investments
 
$
2,710

 
 
 

(E) Reflects the write-off of HCT’s historical deferred financing costs, which were not assigned any value in the preliminary purchase price allocation.

(F) Reflects adjustments to eliminate assets of HCT included in the historical consolidated financial information that Ventas is not acquiring as part of the working capital consideration, net of other acquired assets, primarily consisting of approximately $150 million of other intangible assets.




(G) Reflects the following adjustments (in millions):

Write-off of HCT’s historical fair value of debt adjustments
 
$
(4
)
Fair value of debt adjustment recorded in connection with the acquisition
 
11

HCT debt anticipated to be repaid at closing
 
(508
)
Anticipated borrowings under Ventas’s unsecured revolving credit facility
 
708

Pro forma adjustment to debt
 
$
207

 
 
 

(H) Reflects adjustments to eliminate historical other liabilities of HCT that were not assigned any value in the preliminary purchase price allocation and the recording of approximately $31 million of various lease intangibles, which were recorded based on preliminary fair value calculations.

(I) Reflects the adjustment to record the fair value of the redeemable OP unitholder interests, which are valued at a price of $11.33 per unit (the acquisition value of each share of HCT common stock at the time the acquisition was announced).

(J) Reflects the write-off of HCT’s historical equity, net of the issuance of 26.9 million shares of Ventas common stock in connection with the HCT acquisition, which are valued at $1.8 billion

(K) Reflects the adjustment to record the reclassification of HCT’s historical noncontrolling interest value to redeemable OP unitholder interests.

NOTE 3 - ADJUSTMENTS TO UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(L) Adjustments reflect the effect on Ventas’s and HCT’s historical consolidated statements of income of Ventas’s and HCT’s respective significant 2014 and 2013 transactions, as if those transactions were consummated on January 1, 2013.  With respect to Ventas, these adjustments primarily relate to certain acquisitions and dispositions (including its August 2014 acquisition of 29 independent living seniors housing communities located in Canada) and debt repayments and issuances.  With respect to HCT, these adjustments primarily relate to various asset acquisitions.

(M) Reflects the net amortization of above and below market lease intangibles recorded by Ventas as a result of the HCT acquisition and the elimination of HCT’s historical amortization related to above and below market lease intangibles.

(N) Reflects the elimination of HCT’s historical revenues attributable to assets that Ventas is not acquiring as part of the acquisition.

(O) Reflects the following adjustments (in millions):

 
 
For the Six Months Ended June 30, 2014
 
For the Year Ended December 31, 2013
Write-off of HCT’s historical fair value of debt adjustments
 
$
1

 
$
1

Fair value of debt adjustment recorded in connection with the acquisition
 
(2
)
 
(4
)
HCT debt anticipated to be repaid at closing
 
(3
)
 
(1
)
Anticipated borrowings under Ventas’s unsecured revolving credit facility
 
5

 
10

Write-off of HCT’s deferred financing costs
 
(3
)
 
(4
)
Pro forma adjustment to interest expense
 
$
(2
)
 
$
2





(P) Based on the preliminary purchase price allocation, Ventas expects to allocate $266 million to land and $2.2 billion to buildings and improvements. Depreciation expense is calculated on a straight-line basis based on Ventas’s purchase price allocation and using a 35-year life for buildings and permanent structural improvements, a five-year life for furniture and equipment and a ten-year life for land improvements. Additionally, Ventas’s purchase price allocation includes $180 million of acquired in-place lease intangibles. Further, the adjustment reflects the elimination of historical depreciation and amortization expense.

(Q) Reflects the elimination of costs and fees directly attributable to the merger and fees associated with the ultimate disposition of HCT’s assets.

(R) Reflects the elimination of HCT’s noncontrolling interest that Ventas is not acquiring as part of the acquisition.

(S) Reflects the issuance of 26.9 million shares of Ventas common stock upon consummation of the HCT acquisition, including the impact of redeemable OP units issued on the acquisition date.






NOTE 4 - FUNDS FROM OPERATIONS AND NORMALIZED FUNDS FROM OPERATIONS
 
Ventas’s historical and pro forma funds from operations (“FFO”) and normalized FFO for the six months ended June 30, 2014 and the year ended December 31, 2013 are summarized as follows (in thousands):

VENTAS, INC.
UNAUDITED PRO FORMA FFO AND NORMALIZED FFO
For the six months ended June 30, 2014
(In thousands, except per share amounts)
 
Ventas Historical
 
Ventas 2014 Transactions Adjustments
 
Pro Forma for Ventas 2014 Transactions
 
HCT Historical
 
HCT 2014 Transactions Adjustments
 
Pro Forma for HCT 2014 Transactions
 
HCT Acquisition Adjustments
 
Total Pro Forma
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Income (loss) from continuing operations attributable to common stockholders
$
256,669

 
$
(13,663
)
 
$
243,006

 
$
(104,324
)
 
$
7,934

 
$
(96,390
)
 
$
90,524

 
$
237,140

Discontinued operations
2,776

 
(854
)
 
1,922

 

 

 

 

 
1,922

Net income (loss) attributable to common stockholders
259,445

 
(14,517
)
 
244,928

 
(104,324
)
 
7,934

 
(96,390
)
 
90,524

 
239,062

Adjustments:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Real estate depreciation and amortization
381,262

 
29,424

 
410,686

 
60,523

 
7,303

 
67,826

 
(18,520
)
 
459,992

Real estate depreciation related to noncontrolling interest
(5,305
)
 

 
(5,305
)
 

 

 

 

 
(5,305
)
Real estate depreciation related to unconsolidated entities
2,989

 

 
2,989

 

 

 

 

 
2,989

(Gain) loss on real estate dispositions, net
(12,889
)
 
14,771

 
1,882

 

 

 

 

 
1,882

Discontinued operations:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gain on real estate dispositions, net
(1,483
)
 
1,058

 
(425
)
 

 

 

 

 
(425
)
Depreciation on real estate assets
1,528

 
(159
)
 
1,369

 

 

 

 

 
1,369

FFO
625,547

 
30,577

 
656,124

 
(43,801
)
 
15,237

 
(28,564
)
 
72,004

 
699,564

Adjustments:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Change in fair value of financial instruments
41

 

 
41

 

 

 

 

 
41

Income tax expense
6,407

 

 
6,407

 

 

 

 

 
6,407

Loss on extinguishment of debt, net
2,114

 
(243
)
 
1,871

 

 

 

 

 
1,871

Merger-related expenses and deal costs
20,363

 
(8,398
)
 
11,965

 
25,878

 
(6,428
)
 
19,450

 

 
31,415

Amortization of other intangibles
511

 

 
511

 

 

 

 

 
511

Normalized FFO
$
654,983

 
$
21,936

 
$
676,919

 
$
(17,923
)
 
$
8,809

 
$
(9,114
)
 
$
72,004

 
$
739,809




Ventas’s historical and pro forma FFO and normalized FFO per diluted share outstanding for the six months ended June 30, 2014 follows (in thousands, except per share amounts) (1):
 
Ventas Historical
 
Total Pro Forma
 
 
 
 
Income from continuing operations attributable to common stockholders
$
0.87

 
$
0.73

Discontinued operations
0.01

 
0.01

Net income attributable to common stockholders
0.88

 
0.74

Adjustments:
 
 
 
Real estate depreciation and amortization
1.29

 
1.42

Real estate depreciation related to noncontrolling interest
(0.02
)
 
(0.02
)
Real estate depreciation related to unconsolidated entities
0.01

 
0.01

(Gain) loss on real estate dispositions, net
(0.04
)
 
0.01

Discontinued operations:
 
 
 
Gain on real estate dispositions, net
(0.01
)
 
(0.00
)
Depreciation on real estate assets
0.01

 
0.00

FFO
2.11

 
2.16

Adjustments:
 
 
 
Change in fair value of financial instruments
0.00

 
0.00

Income tax expense
0.02

 
0.02

Loss on extinguishment of debt, net
0.01

 
0.01

Merger-related expenses and deal costs
0.07

 
0.10

Amortization of other intangibles
0.00

 
0.00

Normalized FFO
$
2.21

 
$
2.29

 
 
 
 
Dilutive shares outstanding used in computing FFO and normalized FFO per common share
296,369

 
323,283

 
 
(1) Per share amounts may not add due to rounding.



VENTAS, INC.
UNAUDITED PRO FORMA FFO AND NORMALIZED FFO
For the year ended December 31, 2013
(In thousands, except per share amounts)
 
Ventas Historical
 
Ventas 2014 and 2013 Transactions Adjustments
 
Pro Forma for Ventas 2014 and 2013 Transactions
 
HCT Historical
 
HCT 2014 and 2013 Transactions Adjustments
 
Pro Forma for HCT 2014 and 2013 Transactions
 
HCT Acquisition Adjustments
 
Total Pro Forma
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Income (loss) from continuing operations attributable to common stockholders
$
488,930

 
$
(2,000
)
 
$
486,930

 
$
(22,230
)
 
$
19,304

 
$
(2,926
)
 
$
(6,371
)
 
$
477,633

Discontinued operations
(35,421
)
 
2,154

 
(33,267
)
 

 

 

 

 
(33,267
)
Net income (loss) attributable to common stockholders
453,509

 
154

 
453,663

 
(22,230
)
 
19,304

 
(2,926
)
 
(6,371
)
 
444,366

Adjustments:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Real estate depreciation and amortization
716,412

 
108,216

 
824,628

 
66,975

 
60,583

 
127,558

 
4,960

 
957,146

Real estate depreciation related to noncontrolling interest
(10,512
)
 

 
(10,512
)
 

 

 

 

 
(10,512
)
Real estate depreciation related to unconsolidated entities
6,543

 

 
6,543

 

 

 

 

 
6,543

Gain on re-measurement of equity interest upon acquisition, net
(1,241
)
 

 
(1,241
)
 

 

 

 

 
(1,241
)
Gain on real estate dispositions, net

 
(14,771
)
 
(14,771
)
 

 

 

 

 
(14,771
)
Discontinued operations:
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Gain on real estate dispositions, net
(4,059
)
 
1,262

 
(2,797
)
 

 

 

 

 
(2,797
)
Depreciation on real estate assets
47,806

 
(2,892
)
 
44,914

 

 

 

 

 
44,914

FFO
1,208,458

 
91,969

 
1,300,427

 
44,745

 
79,887

 
124,632

 
(1,411
)
 
1,423,648

Adjustments:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Change in fair value of financial instruments
449

 

 
449

 

 

 

 

 
449

Income tax benefit
(11,828
)
 

 
(11,828
)
 

 

 

 

 
(11,828
)
Loss on extinguishment of debt, net
1,048

 
243

 
1,291

 

 

 

 

 
1,291

Merger-related expenses and deal costs
21,560

 
(7,276
)
 
14,284

 
13,606

 
(15,239
)
 
(1,633
)
 

 
12,651

Amortization of other intangibles
1,022

 

 
1,022

 

 

 

 

 
1,022

Normalized FFO
$
1,220,709

 
$
84,936

 
$
1,305,645

 
$
58,351

 
$
64,648

 
$
122,999

 
$
(1,411
)
 
$
1,427,233




Ventas’s historical and pro forma FFO and normalized FFO per diluted share outstanding for the year ended December 31, 2013 follows (in thousands, except per share amounts) (1):
 
Ventas Historical
 
Total Pro Forma
 
 
 
 
Income from continuing operations attributable to common stockholders
$
1.66

 
$
1.48

Discontinued operations
(0.12
)
 
(0.10
)
Net income attributable to common stockholders
1.54

 
1.38

Adjustments:
 
 
 
Real estate depreciation and amortization
2.43

 
2.97

Real estate depreciation related to noncontrolling interest
(0.04
)
 
(0.03
)
Real estate depreciation related to unconsolidated entities
0.02

 
0.02

Gain on re-measurement of equity interest upon acquisition, net
(0.00
)
 
(0.00
)
Gain on real estate dispositions, net

 
(0.05
)
Discontinued operations:
 
 
 
Gain on real estate dispositions, net
(0.01
)
 
(0.01
)
Depreciation on real estate assets
0.16

 
0.14

FFO
4.09

 
4.42

Adjustments:
 
 
 
Change in fair value of financial instruments
0.00

 
0.00

Income tax benefit
(0.04
)
 
(0.04
)
Loss on extinguishment of debt, net
0.00

 
0.00

Merger-related expenses and deal costs
0.07

 
0.04

Amortization of other intangibles
0.00

 
0.00

Normalized FFO
$
4.14

 
$
4.43

 
 
 
 
Dilutive shares outstanding used in computing FFO and normalized FFO per common share
295,110

 
322,024

 
 
(1) Per share amounts may not add due to rounding.









Unaudited pro forma FFO and normalized FFO are presented herein for informational purposes only and are based on available information and assumptions that the Company’s management believes to be reasonable; however, they are not necessarily indicative of what Ventas’s FFO or normalized FFO actually would have been assuming the transactions had occurred as of the dates indicated.
 
Historical cost accounting for real estate assets implicitly assumes that the value of real estate assets diminishes predictably over time.  However, since real estate values historically have risen or fallen with market conditions, many industry investors deem presentations of operating results for real estate companies that use historical cost accounting to be insufficient by themselves.  To overcome this problem, Ventas considers FFO and normalized FFO to be appropriate measures of operating performance of an equity REIT.  In particular, Ventas believes that normalized FFO is useful because it allows investors, analysts and Ventas management to compare Ventas’s operating performance to the operating performance of other real estate companies and between periods on a consistent basis without having to account for differences caused by unanticipated items and other events such as transactions and litigation.  In some cases, Ventas provides information about identified non-cash components of FFO and normalized FFO because it allows investors, analysts and Ventas management to assess the impact of those items on Ventas’s financial results.

Ventas uses the National Association of Real Estate Investment Trusts (“NAREIT”) definition of FFO.  NAREIT defines FFO as net income (computed in accordance with GAAP), excluding gains (or losses) from sales of real estate property, including gain on re-measurement of equity method investments, and impairment write-downs of depreciable real estate, plus real estate depreciation and amortization, and after adjustments for unconsolidated partnerships and joint ventures.  Adjustments for unconsolidated partnerships and joint ventures will be calculated to reflect FFO on the same basis.  Ventas defines normalized FFO as FFO excluding the following income and expense items (which may be recurring in nature): (a) merger-related costs and expenses, including amortization of intangibles, transition and integration expenses, and deal costs and expenses, including expenses and recoveries relating to the Company’s acquisition lawsuits; (b) the impact of any expenses related to asset impairment and valuation allowances, the write-off of unamortized deferred financing fees, or additional costs, expenses, discounts, make-whole payments, penalties or premiums incurred as a result of early retirement or payment of the Company’s debt; (c) the non-cash effect of income tax benefits or expenses and derivative transactions that have non-cash mark-to-market impacts on the Company’s consolidated statements of income; (d) the impact of future acquisitions or divestitures (including pursuant to tenant options to purchase) and capital transactions; (e) the financial impact of contingent consideration, severance-related costs, charitable donations made to the Ventas Charitable Foundation, gains and losses for non-operational foreign currency hedge agreements and changes in the fair value of financial instruments; and (f) expenses related to the re-audit and re-review of the Company’s historical financial statements and related matters.
 
FFO and normalized FFO presented herein may not be identical to FFO and normalized FFO presented by other real estate companies due to the fact that not all real estate companies use the same definitions.  FFO and normalized FFO should not be considered as alternatives to net income (determined in accordance with GAAP) as indicators of Ventas’s financial performance or as alternatives to cash flow from operating activities (determined in accordance with GAAP) as measures of Ventas’s liquidity, nor is FFO and normalized FFO necessarily indicative of sufficient cash flow to fund all of Ventas’s needs.  Ventas believes that in order to facilitate a clear understanding of Ventas’s consolidated historical operating results, FFO and normalized FFO should be examined in conjunction with net income as presented in the unaudited pro forma condensed consolidated financial statements.